Advancements in research have led to the identification of a growing number of genetic and neuroimaging markers of migraine.
Many translational barriers exist between preclinical research and clinical practice.
Published interim results of ongoing clinical trials often report analyses without justification and may mislead clinicians about whether a particular drug or therapy is beneficial.
The benefits associated with medical cannabis therapy may be overestimated due to inadequate blinding in clinical trials.
Scientists continue to be the targets of legal action from pharmaceutical, medical device, and nutraceutical companies when published studies frame these companies' products in an unfavorable light.
Researchers have created a set of 21 candidate criteria for systemic lupus erythematosus as apart of a multiphase development of a set of criteria for the disease.
The Lupus Foundation of America announced it is accepting applications for 8 research grants to fund lupus research.
In January 2017, the National Academies of Sciences, Engineering, and Medicine released a report titled "The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendation for Research."
The DEA's plan to list kratom as a Schedule I controlled substance would make researching the possible opioid substitute much more difficult.
Clinical Pain Advisor Articles
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Optimal Strategies for Opioid Weaning After Ambulatory Surgery
- Emergency Physicians Offer Recommendations for Identifying and Managing Opioid Use Disorder
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness